Optune Lua for the treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM) to be used concurrently with pemetrexed and platinum-based chemotherapy

  • Enrollment

    This study is not currently enrolling.

  • Research Area

    Clinical Cancer Research

  • Principal Investigator

    George Simon

  • Sponsor

    Novocur Ltd

Optune Lua is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma (“MPM”) to be used concurrently with pemetrexed and platinum-based chemotherapy.